NCT05181241 - A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

December 25, 2017

Study Completion Date

April 25, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

Dimolegin

"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"

Trial Locations (1)

125315

Non-Governmental Private Healthcare Institution of Sci-entific Clinical Center of Russian Railways JSC, Moscow